Based on the company’s animal studies, ImmuneRegen BioSciences’ Viprovex™ has demonstrated potential for treating potentially resurgent Spanish Flu (H1N1), Avian Flu (H5N1) and other infectious diseases.
Viprovex™ is the trade name used in referring to formulations of Homspera for potential indications for treatment of viral and bacterial infections.
Homspera, on the other hand, is a generic name used by ImmuneRegen to describe the synthetic peptide Sar9, Met (O2)11-Substance P - an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout the body, including in the airways of humans and many other species.
ImmuneRegen BioSciences is a wholly-owned subsidiary of IR BioSciences Holdings, Inc. (OTC: IRBO).
Find more details from the full report.
.jpg)
Comment Preview